C-KFAJneural exosomes, blood-brain barrier, neuroregeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop binding agents and uses for central nervous system delivery.
Patent-protected binding-agent technology for CNS delivery assigned to Aruna Bio Inc.
EP4142737A4 was published on 2024-06-05 and listed as pending in the supplied patent record.
Use neural cell extracellular vesicles for nervous-system diseases and injuries, with supplied patent keywords including EVs, cells, composition, neural, and stroke.
Patent-described neural cell extracellular vesicle compositions and uses, originally assigned to Aruna Biomedical Inc and University of Georgia entities.
WO2017087500A1 was published on 2017-05-26; the supplied patent record lists legal status as ceased.
Treat acute neurological conditions and chronic neurodegenerative diseases by delivering neural cell-derived exosomes across the blood-brain barrier to reduce neuro-inflammation and promote neuro-protection and neuro-regeneration.
Therapeutic neural exosome candidate derived from Aruna Bio's proprietary neural cell-derived exosome platform.
Listed on Aruna Bio's pipeline as the company's therapeutic exosome candidate for neurological disease.
Site analysis states AB126 gains access across the blood-brain barrier and acts through reduced neuro-inflammation, neuro-protection, and neuro-regeneration; no clinical results were supplied.
Treat brain cancers such as glioblastoma by delivering doxorubicin to the CNS using human neural stem cell-derived extracellular vesicles.
Doxorubicin payload loaded into hNSC-EVs using alkaline passive loading, tested for glioma cytotoxicity and BBB penetration.
A 2026 Scientific Reports study reported proof-of-concept efficacy and delivery data for doxorubicin-loaded hNSC-EVs.
The loaded EVs were cytotoxic to glioma cells in vitro and had higher BBB penetrance than doxorubicin alone in vivo.
Enable delivery of therapeutics across the blood-brain barrier and blood-tumor barrier for CNS diseases including brain cancers and neurodegenerative diseases.
Human neural stem cell-derived extracellular vesicles produced using a suspension neurosphere system, with alkaline passive loading of drug payloads.
A 2026 Scientific Reports publication described alkaline loading of doxorubicin into hNSC-EVs and demonstrated CNS delivery proof of concept.
Doxorubicin-loaded hNSC-EVs induced cytotoxicity in glioma cells in vitro and showed higher BBB penetrance than doxorubicin alone in vivo.
Improve outcomes after acute ischemic stroke beyond reperfusion therapy using neural stem cell-derived extracellular vesicles.
Rat acute ischemic stroke model testing single-dose, two-dose, and three-dose regimens of NSC EV over 48 hours, with functional outcomes, infarct volume, neurologic score, and serum NfL readouts.
A 2026 Translational Stroke Research study evaluated dose regimens in a rat AIS model and identified a three-dose regimen over 48 hours as producing the best outcomes.
Three-dose NSC EV treatment reduced infarct volume, improved neurologic score, and reduced serum neurofilament light chain; single-dose and two-dose regimens were effective on some endpoints.
Provide a translational biomarker that predicts acute ischemic stroke outcome and can measure treatment effects of neural stem cell-derived extracellular vesicles.
Serum biomarker assessment in a rat AIS model, comparing NfL with infarct volume, ICAM-1, and S100B against functional outcomes.
A 2026 Translational Stroke Research study reported serum NfL correlated strongly with functional outcomes and reflected NSC EV treatment effects.
NfL predicted outcomes about as well as infarct volume and outperformed ICAM-1 and S100B in the described rat stroke model.